What is in Wegovy that Causes Weight Loss?

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy contains semaglutide, a medication that activates glucagon-like peptide-1 (GLP-1) receptors in the brain and digestive system. Clinical trials show semaglutide helps patients lose 15-22% of body weight over 68 weeks. PlexusDx delivers compounded semaglutide injections from licensed 503A pharmacies at a fraction of brand-name costs.

How Semaglutide Works in Your Body

Semaglutide is a GLP-1 receptor agonist, meaning it binds to and activates GLP-1 receptors throughout your central nervous system and gastrointestinal tract. When you take semaglutide, it activates satiety centers in your hypothalamus—the brain region responsible for hunger and fullness signals. This activation tells your brain you are satisfied faster during meals, naturally reducing calorie intake without willpower-based restriction.

Beyond appetite suppression, semaglutide slows gastric emptying, the rate at which food leaves your stomach. A slower stomach-to-intestine transit time means food stays in your digestive system longer, keeping you full between meals and preventing rapid blood sugar spikes that trigger renewed hunger. This dual mechanism—central appetite reduction plus delayed digestion—creates sustained satiety that supports consistent weight loss over months.

The GLP-1 Receptor and Its Role in Weight Loss

GLP-1 receptors exist on neurons in your appetite-control centers, on pancreatic beta cells, and throughout your gut lining. When semaglutide activates these receptors, it triggers a cascade of signals that decrease orexigenic neurotransmitters (chemicals that drive hunger) while increasing anorexigenic signals (those that promote satiety). This receptor activation is highly specific, affecting pathways linked directly to energy balance rather than causing broad stimulation or sedation.

Your body naturally produces small amounts of GLP-1 after meals, which is why appetite naturally decreases as food enters your system. Semaglutide is engineered to be a long-acting version of this natural hormone—it persists in your bloodstream for seven days after a weekly injection, maintaining steady appetite suppression 24/7. This continuous activation prevents the hunger rebound that often follows short-acting appetite suppressants.

Clinical Evidence: What Studies Show About Semaglutide Weight Loss

The STEP trials (Semaglutide Treatment Effect in People with obesity) enrolled over 4,500 participants across four studies. Participants receiving semaglutide 2.4 mg weekly lost an average of 15-22% of baseline body weight, while placebo groups lost only 2-3%. These results held across diverse populations, including those with type 2 diabetes, and weight loss benefits persisted as long as patients continued the medication.

Beyond weight loss, STEP trial participants showed improvements in cardiovascular risk factors: reduced blood pressure, improved cholesterol profiles, and better blood sugar control. Many patients experienced relief from joint pain, improved sleep quality, and increased physical activity tolerance—benefits that stem partly from carrying less weight and partly from semaglutide's direct effects on metabolic regulation. These outcomes suggest semaglutide addresses root causes of weight gain rather than masking hunger temporarily.

Semaglutide Alternatives: Compounded Options at Lower Cost

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan from licensed 503A compounding pharmacies. Unlike Wegovy (brand-name semaglutide), compounded versions are bioidentical to the active ingredient but produced in licensed pharmacy facilities rather than pharmaceutical manufacturing plants. PlexusDx serves all 50 states, requires no insurance, charges no membership fees, and accepts HSA and FSA payments for maximum affordability.

PlexusDx also provides oral semaglutide, microdose GLP-1 protocols, and advanced combination therapies like GLP-Squared (semaglutide plus tirzepatide) for patients seeking enhanced results. All medications are made by licensed 503A compounding pharmacies and shipped directly to your home. Your dose may need to go up as your body adjusts, but PlexusDx pricing remains flat—you pay the same monthly rate regardless of dose strength.

Genetic Factors That Influence Your Semaglutide Response

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The Precision Peptide test costs $298, allowing you to start therapy immediately while gathering personalized data. Understanding your peptide pathway genetics empowers your PlexusDx provider to tailor dosing, select the best medication formulation, and anticipate side effects—transforming weight loss treatment from one-size-fits-all to precision medicine aligned with your unique biochemistry.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does semaglutide work immediately, or does it take time to feel hungry reduction?

Most patients notice reduced appetite within 2-4 weeks of starting semaglutide, though the effect builds gradually as your dose increases each week. Peak satiety benefits typically emerge 4-8 weeks into treatment. PlexusDx providers follow a slow-titration schedule to maximize tolerance and give your body time to adjust to the hunger-suppressing signal.

What happens to weight loss if you stop taking semaglutide?

Clinical data shows weight regains over 1-2 years if semaglutide is discontinued, though the rate varies by individual and lifestyle changes made during treatment. Semaglutide works only while you use it; it does not permanently rewire your appetite system. Many patients transition to maintenance therapy or lower doses to sustain results long-term.

How much does semaglutide cost with PlexusDx compared to Wegovy?

PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, while brand-name Wegovy typically costs $900+ monthly without insurance. PlexusDx charges no membership, insurance, or setup fees and serves all 50 states. HSA and FSA accounts cover PlexusDx medications, lowering your out-of-pocket cost further.

Are there side effects from semaglutide, and how serious are they?

Common side effects include nausea, constipation, and reduced appetite for certain foods—most mild and temporary. Rare but serious risks include pancreatitis and gallbladder issues. PlexusDx screening includes medical history review to identify contraindications, and your provider monitors symptoms closely during titration.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx Precision Peptide Genetic Test analyzes GIPR and FTO, and MC4R variants to reveal your genetic predisposition to GLP-1 response. Certain genetic profiles correlate with stronger semaglutide efficacy, while others may benefit from dual-compound therapy like GLP-Squared. The test costs $99 and is available one month after starting treatment.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.